Vanguard Group Inc Arcellx, Inc. Transaction History
Vanguard Group Inc
- $5.57 Trillion
- Q4 2024
A detailed history of Vanguard Group Inc transactions in Arcellx, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 3,330,092 shares of ACLX stock, worth $212 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
3,330,092
Previous 2,462,096
35.25%
Holding current value
$212 Million
Previous $206 Million
23.35%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding ACLX
# of Institutions
224Shares Held
45.9MCall Options Held
2.21MPut Options Held
887K-
Paradigm Biocapital Advisors LP New York, NY4MShares$255 Million12.04% of portfolio
-
Perceptive Advisors LLC New York, NY3.89MShares$248 Million8.48% of portfolio
-
Nea Management Company, LLC Timonium, MD3.75MShares$239 Million23.89% of portfolio
-
Black Rock Inc. New York, NY3.52MShares$224 Million0.0% of portfolio
-
Sr One Capital Management, LP2.35MShares$150 Million66.54% of portfolio
About Arcellx, Inc.
- Ticker ACLX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,819,200
- Market Cap $2.79B
- Description
- Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It...